<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2580427755-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2580427755-430x241.jpg"/></p>
<p>该协议使 Ipsen 获得了大中华区以外的癌症治疗的全球权利。HJBC via Shutterstock.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/10/Syngene-Pharma-1024x101-1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/10/Syngene-Pharma-1024x101-1.jpg"/></p>
<p>Ipsen 已将一款中国开发的抗体药物偶联物（ADC）纳入其产品线，此交易可能超过 10 亿美元，巩固了这一抗肿瘤模式在 2025 年交易中的突出表现。</p>
<p>这家法国制药公司与 Simcere Zaiming 签署了一项许可协议，涉及 SIM0613 这一 ADC 资产，预计将在 2026 年开始临床开发。该协议使 Ipsen 获得了大中华区以外的癌症治疗的全球权利，Simcere Zaiming 有资格获得高达 10.6 亿美元的预付款、开发、监管和商业里程碑付款。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>Ipsen 将拥有生产权，并负责 I 期准备活动和监管申请的提交。根据 Ipsen 的说法，该疗法在多个体内预临床模型中表现出 “强劲的肿瘤缩小”。该制药公司计划在 2026 年下半年启动一项评估 SIM0613 在癌症患者中应用的 I 期试验。</p>
<p>SIM0613 靶向富含亮氨酸重复序列的蛋白 15（LRRC15），该蛋白在各种肿瘤类型和癌症相关成纤维细胞中高度表达，但在正常细胞中的表达有限。与其他 ADC 一样，该药物采用靶向方式，杀死癌细胞而不损伤健康细胞。</p>
<p>Ipsen 首次希望通过与 Sutro Biopharma 的交易将一款 ADC 纳入其产品组合，该交易价值高达 9 亿美元，但最终决定不推进该交易中涉及的资产。几个月后，Ipsen 通过与 Foreseen Biotechnology 的 10 亿美元协议又增加了一款 ADC。</p>
<p>Ipsen 的研发负责人 Christelle Huguet 表示：“今天的公告强调了我们在创新方面的大胆愿景，以及塑造肿瘤学未来的决心。”</p>
<p>Ipsen 在肿瘤学领域进行了重大推动，旨在成为该领域的主要参与者。自 2020 年以来，该公司已增加了 20 多个早期阶段的项目。</p>
<p>许多制药公司今年在 ADC 交易上进行了大量投资，以获取市场增长。根据 GlobalData 的分析，ADCs 是一类快速增长的药物，预计到 2030 年收入将超过 450 亿美元。</p>
<p>2025 年 1 月，Boehringer Ingelheim 与 Synaffix 签署了一项价值 13 亿美元的许可协议，涉及多个未披露靶点的 ADC 技术。今年，罗氏签署了三项 ADC 交易，最新的一项是在 3 月与 Oxford BioTherapeutics 达成的协议，可能超过 10 亿美元。12 月初，美国的 Crescent Biopharma 为中国的 Kelun-Biotech 的 ITGB6 靶向 ADC 支付了 12.5 亿美元。</p>
<p>Kelun-Biotech 是 2025 年参与 ADC 交易的众多中国公司之一，该国因其在开发这一模式方面的专业性而闻名。GlobalData 的分析显示，全球活跃管线 ADC 数量前 10 家公司中有一半位于中国。</p>
<p>基于 ADC 的交易帮助推动了自 2020 年以来西方和中国制药公司之间许可交易价值的 280% 激增。</p>
<p>Simcere 的工作今年已经引起了大型制药公司的关注，AbbVie 在 1 月以 10 亿美元的交易从该公司获得了一种三特异性抗体。</p>
<p><em>Pharmaceutical Technology（或 Clinical Trials Arena）上的 ADC 内容由 Syngene 支持。</em> <em>编辑内容独立制作，遵循_最高标准_的新闻诚信。主题赞助商不参与编辑内容的创作。</em></p>
<h2>制药技术卓越奖 - 提名已关闭</h2>
<p><strong>制药技术卓越奖</strong> 的提名现已关闭。感谢所有参与的组织——你们的反应非常出色，展示了卓越的创新、领导力和影响力。</p>
<p><strong>行动中的卓越</strong></p>
<p>Upperton Pharma Solutions 因在 <strong>综合制造</strong> 方面的业务扩展而获得 2025 年制药技术卓越奖。Upperton 正在迅速扩大其在英国的 GMP 和无菌制造足迹。了解 Upperton 的综合 CDMO 模型如何帮助制药公司从早期开发过渡到临床和小众商业供应，减少交接和加快时间表。</p>
<p><strong>发现影响</strong></p>

ADCT

<p>Ipsen 与 Simcere Zaiming 签署了一项价值 10 亿美元的许可协议，获得 ADC 资产 SIM0613 在大中华区以外的全球权利。该药物靶向 LRRC15，在临床前模型中显示出良好前景。Ipsen 计划于 2026 年开展 I 期临床试验，旨在扩展其肿瘤学产品组合。ADC 交易正在蓬勃发展，Ipsen 和其他制药公司在这一不断增长的药物类别中进行了大量投资</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2580427755-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2580427755-430x241.jpg"/></p>
<p>The agreement sees Ipsen secure global rights for the cancer treatment outside of Greater China. HJBC via Shutterstock.com.</p>
<div class="lb-trans"><p>该协议使 Ipsen 获得了大中华区以外的癌症治疗的全球权利。HJBC via Shutterstock.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/10/Syngene-Pharma-1024x101-1.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/10/Syngene-Pharma-1024x101-1.jpg"/></p>
<p>Ipsen has added a Chinese-developed antibody drug conjugate (ADC) to its pipeline in a deal that could top $1bn, cementing the anti-tumour modality’s status as one of the standout performers in dealmaking in 2025.</p>
<div class="lb-trans"><p>Ipsen 已将一款中国开发的抗体药物偶联物（ADC）纳入其产品线，此交易可能超过 10 亿美元，巩固了这一抗肿瘤模式在 2025 年交易中的突出表现。</p>
</div><p>The French drugmaker has signed a licensing deal with Simcere Zaiming for SIM0613, an ADC asset due to start clinical development in 2026. The agreement sees Ipsen secure global rights for the cancer treatment outside of Greater China, with Simcere Zaiming eligible for upfront, development, regulatory and commercial milestone payments that could reach $1.06bn.</p>
<div class="lb-trans"><p>这家法国制药公司与 Simcere Zaiming 签署了一项许可协议，涉及 SIM0613 这一 ADC 资产，预计将在 2026 年开始临床开发。该协议使 Ipsen 获得了大中华区以外的癌症治疗的全球权利，Simcere Zaiming 有资格获得高达 10.6 亿美元的预付款、开发、监管和商业里程碑付款。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Ipsen will have manufacturing rights, along with taking charge of Phase I preparation activities and submission of regulatory applications. The therapy has demonstrated “robust tumour regressions in multiple <em>in vivo</em> preclinical models”, according to Ipsen. The pharma company is eyeing the launch of a Phase I trial evaluating SIM0613 in cancer patients in the second half of 2026.</p>
<div class="lb-trans"><p>Ipsen 将拥有生产权，并负责 I 期准备活动和监管申请的提交。根据 Ipsen 的说法，该疗法在多个体内预临床模型中表现出 “强劲的肿瘤缩小”。该制药公司计划在 2026 年下半年启动一项评估 SIM0613 在癌症患者中应用的 I 期试验。</p>
</div><p>SIM0613 targets the leucine-rich repeat-containing 15 (LRRC15), a protein highly expressed on various tumour types and cancer-associated fibroblasts but with limited expression on normal cells. Like other ADCs, the drug works in a targeted approach, killing cancer cells while sparing healthy ones.</p>
<div class="lb-trans"><p>SIM0613 靶向富含亮氨酸重复序列的蛋白 15（LRRC15），该蛋白在各种肿瘤类型和癌症相关成纤维细胞中高度表达，但在正常细胞中的表达有限。与其他 ADC 一样，该药物采用靶向方式，杀死癌细胞而不损伤健康细胞。</p>
</div><p>Ipsen first looked to add an ADC to its portfolio via a deal that would have been worth up to $900m with Sutro Biopharma in April 2024, though it decided not to advance the asset involved in the transaction. A second ADC was added just a few months later in July via a $1bn pact with Foreseen Biotechnology.</p>
<div class="lb-trans"><p>Ipsen 首次希望通过与 Sutro Biopharma 的交易将一款 ADC 纳入其产品组合，该交易价值高达 9 亿美元，但最终决定不推进该交易中涉及的资产。几个月后，Ipsen 通过与 Foreseen Biotechnology 的 10 亿美元协议又增加了一款 ADC。</p>
</div><p>Ipsen’s head of R&amp;D, Christelle Huguet, said: “Today’s announcement underscores our bold vision to lead innovation and shape the future of oncology.”</p>
<div class="lb-trans"><p>Ipsen 的研发负责人 Christelle Huguet 表示：“今天的公告强调了我们在创新方面的大胆愿景，以及塑造肿瘤学未来的决心。”</p>
</div><p>Ipsen has been making a major push in oncology as it aims to become a major player in the sector. The company has added more than 20 early-stage programmes since 2020.</p>
<div class="lb-trans"><p>Ipsen 在肿瘤学领域进行了重大推动，旨在成为该领域的主要参与者。自 2020 年以来，该公司已增加了 20 多个早期阶段的项目。</p>
</div><p>Many pharma companies have invested heavily in ADC deals this year as a means of accessing the market’s growth. ADCs are a rapidly growing drug class, with forecast revenues soaring to over $45bn by 2030, according to analysis by GlobalData, parent company of <em>Pharmaceutical Technology</em>.</p>
<div class="lb-trans"><p>许多制药公司今年在 ADC 交易上进行了大量投资，以获取市场增长。根据 GlobalData 的分析，ADCs 是一类快速增长的药物，预计到 2030 年收入将超过 450 亿美元。</p>
</div><p>In January 2025, Boehringer Ingelheim spent $1.3bn on a licensing deal with Synaffix for ADC technology on several undisclosed targets. Roche has signed three ADC deals this year, with the latest dating back to March via an agreement with Oxford BioTherapeutics that could surpass $1bn. Earlier in December, US-based Crescent Biopharma outlaid $1.25bn for China-based Kelun-Biotech’s ITGB6-directed ADC.</p>
<div class="lb-trans"><p>2025 年 1 月，Boehringer Ingelheim 与 Synaffix 签署了一项价值 13 亿美元的许可协议，涉及多个未披露靶点的 ADC 技术。今年，罗氏签署了三项 ADC 交易，最新的一项是在 3 月与 Oxford BioTherapeutics 达成的协议，可能超过 10 亿美元。12 月初，美国的 Crescent Biopharma 为中国的 Kelun-Biotech 的 ITGB6 靶向 ADC 支付了 12.5 亿美元。</p>
</div><p>Kelun-Biotech is one of many Chinese companies to be involved in ADC deals in 2025, as the country has become well-known for its speciality in developing the modality. Analysis by GlobalData has identified that half of the top 10 companies by active pipeline ADC count in the world are based in China.</p>
<div class="lb-trans"><p>Kelun-Biotech 是 2025 年参与 ADC 交易的众多中国公司之一，该国因其在开发这一模式方面的专业性而闻名。GlobalData 的分析显示，全球活跃管线 ADC 数量前 10 家公司中有一半位于中国。</p>
</div><p>ADC-based deals have helped fuel the 280% surge in licensing deal value between Western and Chinese pharma companies since 2020.</p>
<div class="lb-trans"><p>基于 ADC 的交易帮助推动了自 2020 年以来西方和中国制药公司之间许可交易价值的 280% 激增。</p>
</div><p>Simcere’s work has already caught the eye of big pharma this year, with AbbVie securing a trispecific antibody from the company in a $1bn deal in January.</p>
<div class="lb-trans"><p>Simcere 的工作今年已经引起了大型制药公司的关注，AbbVie 在 1 月以 10 亿美元的交易从该公司获得了一种三特异性抗体。</p>
</div><p><em>ADC content on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Syngene</em>. <em>Editorial content is independently produced and follows the</em> highest standards <em>of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.</em></p>
<div class="lb-trans"><p><em>Pharmaceutical Technology（或 Clinical Trials Arena）上的 ADC 内容由 Syngene 支持。</em> <em>编辑内容独立制作，遵循_最高标准_的新闻诚信。主题赞助商不参与编辑内容的创作。</em></p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 提名已关闭</h2>
</div><p>Nominations are now closed for the <strong>Pharmaceutical Technology Excellence Awards</strong>. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p><strong>制药技术卓越奖</strong> 的提名现已关闭。感谢所有参与的组织——你们的反应非常出色，展示了卓越的创新、领导力和影响力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行动中的卓越</strong></p>
</div><p>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in <strong>Integrated Manufacturing</strong>, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
<div class="lb-trans"><p>Upperton Pharma Solutions 因在 <strong>综合制造</strong> 方面的业务扩展而获得 2025 年制药技术卓越奖。Upperton 正在迅速扩大其在英国的 GMP 和无菌制造足迹。了解 Upperton 的综合 CDMO 模型如何帮助制药公司从早期开发过渡到临床和小众商业供应，减少交接和加快时间表。</p>
</div><p><strong>Discover the Impact</strong></p>
<div class="lb-trans"><p><strong>发现影响</strong></p>
</div>

Ipsen 斥资 10 亿美元收购中国先声药业的临床前 ADC